var data={"title":"Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/contributors\" class=\"contributor contributor_credentials\">Elaine I Tuomanen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/contributors\" class=\"contributor contributor_credentials\">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/contributors\" class=\"contributor contributor_credentials\">Mary M Torchia, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 03, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Streptococcus pneumoniae</em> (<em>pneumococcus</em>) is a leading cause of serious illness among children worldwide [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/1\" class=\"abstract_t\">1</a>]. Before universal infant immunization with pneumococcal conjugate vaccine in the United States, <em>S. pneumoniae</em> caused approximately 17,000 cases of invasive disease each year among children younger than five years of age, including 700 cases of meningitis and 200 deaths [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/1\" class=\"abstract_t\">1</a>]. It was the most frequent cause of bacteremia, bacterial pneumonia, bacterial meningitis, sinusitis, and acute otitis media [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/1\" class=\"abstract_t\">1</a>].</p><p>The 7-valent pneumococcal conjugate vaccine (PCV7) was added to the schedule of recommended vaccines for children younger than two years of age in the United States in 2000 [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/1,2\" class=\"abstract_t\">1,2</a>]. PCV7 contains serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F conjugated to a mutant of diphtheria toxoid (<a href=\"image.htm?imageKey=PEDS%2F77274\" class=\"graphic graphic_table graphicRef77274 \">table 1</a>). The routine use of PCV7 resulted in a decreased incidence of invasive pneumococcal disease in children. However, there were increasing data to suggest that universal infant immunization with PCV7 changed the serotype patterns of invasive disease, nasopharyngeal (NP) colonization, and antibiotic resistance patterns. In 2010, a <a href=\"topic.htm?path=pneumococcal-conjugate-vaccine-13-valent-drug-information\" class=\"drug drug_general\">13-valent pneumococcal conjugate vaccine</a> replaced PCV7 in the routine childhood immunization schedule [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/3\" class=\"abstract_t\">3</a>].</p><p>The impact of universal infant immunization with PCV7 and PCV13 on invasive serotypes, nasopharyngeal flora, and antibiotic resistance in children in the United States will be reviewed here. The impact in adults is discussed separately. (See <a href=\"topic.htm?path=invasive-pneumococcal-streptococcus-pneumoniae-infections-and-bacteremia#H3\" class=\"medical medical_review\">&quot;Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia&quot;, section on 'Impact of childhood vaccination'</a>.)</p><p>Pneumococcal conjugate and polysaccharide vaccines also are discussed separately. (See <a href=\"topic.htm?path=pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-children\" class=\"medical medical_review\">&quot;Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children&quot;</a> and <a href=\"topic.htm?path=pneumococcal-streptococcus-pneumoniae-polysaccharide-vaccines-in-children\" class=\"medical medical_review\">&quot;Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children&quot;</a> and <a href=\"topic.htm?path=pneumococcal-vaccination-in-adults\" class=\"medical medical_review\">&quot;Pneumococcal vaccination in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EFFICACY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Surveillance after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) to the standard childhood immunization schedule has shown that pneumococcal conjugate vaccines are effective in preventing invasive pneumococcal disease (IPD) and providing herd immunity (<a href=\"image.htm?imageKey=PEDS%2F64834\" class=\"graphic graphic_figure graphicRef64834 \">figure 1</a>). In 2003, it was estimated that 29,599 cases of vaccine serotype IPD were prevented through routine immunization. Approximately two-thirds of these cases were prevented through herd immunity [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/4\" class=\"abstract_t\">4</a>]. The greatest decline has been noted in pneumococcal bacteremia without a focus.</p><p>The efficacy of universal infant immunization with PCV in the United States on the incidence of IPD in children and adults is discussed in detail separately. (See <a href=\"topic.htm?path=pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-children#H8\" class=\"medical medical_review\">&quot;Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children&quot;, section on 'Efficacy and effectiveness'</a> and <a href=\"topic.htm?path=invasive-pneumococcal-streptococcus-pneumoniae-infections-and-bacteremia#H3\" class=\"medical medical_review\">&quot;Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia&quot;, section on 'Impact of childhood vaccination'</a>.)</p><p class=\"headingAnchor\" id=\"H9889776\"><span class=\"h1\">INVASIVE DISEASE CAUSED BY NONVACCINE SEROTYPES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Surveillance of pneumococcal isolates in children with invasive pneumococcal disease (IPD) indicates that, after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) to the routine childhood immunization schedule, there was an increase in the proportion of cases of IPD caused by nonvaccine serotypes (eg, replacement serotypes), including serotypes 19A, 6C, and 22F, and serogroups 15 and 33 (<a href=\"image.htm?imageKey=PEDS%2F64834\" class=\"graphic graphic_figure graphicRef64834 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/4-22\" class=\"abstract_t\">4-22</a>]. However, the increase in IPD caused by nonvaccine serotypes was small compared with the overall decline in IPD [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/4\" class=\"abstract_t\">4</a>].</p><p>The Centers for Disease Control and Prevention (CDC) population-based surveillance from 10 areas of the United States indicates little change in the incidence of IPD caused by nonvaccine serotypes among children younger than five years following the introduction of PCV13 (<a href=\"image.htm?imageKey=PEDS%2F96718\" class=\"graphic graphic_figure graphicRef96718 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/23\" class=\"abstract_t\">23</a>]. However, a 26 percent increase (95% CI 13-44 percent) in IPD caused by non-vaccine serotypes among adults ages 50 to 64 suggests evidence of serotype replacement. Surveillance from eight children's hospitals in the United States following introduction of PCV13 in 2010 indicates that the most common non-PCV13 serotypes isolated from children hospitalized with IPD were 33F, 22F, 12, 15B, 15C, 23A, and 11 [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/24\" class=\"abstract_t\">24</a>].</p><p>Surveillance following introduction of PCV13 in a single state indicates that IPD caused by nonvaccine serotypes was more frequent among children with underlying conditions (eg, chronic lung disease, malignancy, immunosuppressive therapy, asthma, sickle cell disease, asplenia) than children without underlying conditions (27 versus 17 percent) [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/25\" class=\"abstract_t\">25</a>].</p><p>These reports highlight the ability of pneumococcus to adapt to vaccine selective pressure and the need to remain vigilant for the invasive disease caused by nonvaccine serotypes. Factors other than the use of pneumococcal conjugate vaccines (eg, patterns of antibiotic use) may contribute to IPD epidemiology [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/26-28\" class=\"abstract_t\">26-28</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Serotype 19A</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Among children, serotype 19A emerged as an important cause of IPD by replacement serotypes after the introduction of the 7-valent pneumococcal conjugate vaccine [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/16,22,29-31\" class=\"abstract_t\">16,22,29-31</a>]. Serotype 19A also emerged as an important cause of multidrug-resistant acute otitis media, coalescent mastoiditis, and chronic sinusitis [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/32-35\" class=\"abstract_t\">32-35</a>]. Serotype 19A is included in the <a href=\"topic.htm?path=pneumococcal-conjugate-vaccine-13-valent-drug-information\" class=\"drug drug_general\">13-valent pneumococcal conjugate vaccine</a> that was licensed in 2010. Surveillance from eight children's hospitals in the United States following introduction of PCV13 in 2010 demonstrated a 58 percent decline in IPD due to serotype 19A among hospitalized children; but 19A remained the most frequently isolated serotype [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/24\" class=\"abstract_t\">24</a>]. (See <a href=\"topic.htm?path=acute-otitis-media-in-children-epidemiology-microbiology-clinical-manifestations-and-complications#H16\" class=\"medical medical_review\">&quot;Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications&quot;, section on 'Microbiology'</a> and <a href=\"topic.htm?path=pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-children#H3\" class=\"medical medical_review\">&quot;Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children&quot;, section on 'Conjugate vaccines'</a>.) </p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">NASOPHARYNGEAL FLORA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most studies evaluating the effects of universal immunization with the pneumococcal conjugate vaccine (PCV) on nasopharyngeal (NP) carriage have shown that vaccination does not change the overall rate of pneumococcal carriage [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/20,36-44\" class=\"abstract_t\">20,36-44</a>]. However, it does reduce the acquisition of vaccine serotypes and increases the acquisition of nonvaccine serotypes [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/7,20,37-56\" class=\"abstract_t\">7,20,37-56</a>]. </p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">PCV serotypes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Conjugate vaccines reduce NP carriage of the serotypes included in the vaccine (<a href=\"image.htm?imageKey=PEDS%2F77274\" class=\"graphic graphic_table graphicRef77274 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/37-39,45-49,53-56\" class=\"abstract_t\">37-39,45-49,53-56</a>]. This was demonstrated in several pre-licensure investigations of small cohorts of children [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/45,46\" class=\"abstract_t\">45,46</a>], and in post-licensure surveillance of children in Massachusetts:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one study, 275 children (2 to 24 months of age) underwent NP cultures at well-child and acute-care visits for acute otitis media between 2000 and 2003 [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/48\" class=\"abstract_t\">48</a>]. During this time period, NP colonization with PCV7 vaccine serotypes decreased from 22 to 2 percent.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another report, NP cultures were obtained from children &lt;7 years of age at well-child and acute-care visits in primary care practices in Massachusetts communities between 2001 and 2009 [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/37,40,54\" class=\"abstract_t\">37,40,54</a>]. NP colonization with PCV7 vaccine serotypes decreased from 36 to 2 percent.</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Non-PCV serotypes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In contrast to the inhibitory effect on vaccine serotypes, pneumococcal vaccination in children is associated with increases in the nasal carriage of nonvaccine serotypes [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/20,37-40,42,43,46-53\" class=\"abstract_t\">20,37-40,42,43,46-53</a>]. In the Massachusetts surveillance studies described above, NP carriage of nonvaccine serotypes increased from 7 to 16 percent in children 2 to 24 months of age between 2000 and 2003 [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/48\" class=\"abstract_t\">48</a>] and from 15 to 29 percent in children &lt;7 years of age between 2001 and 2007, with significant increases in serotypes 19A, 35B, 23A, and 7F [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/40\" class=\"abstract_t\">40</a>]. The most common nonvaccine serotypes colonizing the NP of the older children were 11, 15, and 29.</p><p>Post-hoc analysis of a large randomized trial on the effect of PCV7 on pneumococcal carriage indicated that nasopharyngeal acquisition of serotype 19A was increased among children who received PCV7 at 2, 4, and 11 months compared with those who were unvaccinated (16.2 versus 9.2 percent, relative risk 1.75, 95% CI 1.14-2.7) [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/57\" class=\"abstract_t\">57</a>]. The proportion of children who had used antibiotics in the six months before nasopharyngeal culture was similar between groups. The clonal distribution of the nasopharyngeal isolates was similar to that of serotype 19A invasive isolates.</p><p>A similar increase in colonization with nonvaccine serotypes has been noted among the younger siblings of PCV9 recipients. In the day care trial described above, a greater proportion of siblings of PCV9 recipients than siblings of control vaccine recipients had NP cultures positive for nonvaccine serotypes (19 versus 13 percent) [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/47\" class=\"abstract_t\">47</a>].</p><p>The clinical implications of these changes in NP colonization remain to be determined. The effect of colonization with nonvaccine serotypes, some of which are penicillin-resistant, will depend upon the ability of the new serotypes to cause local (eg, otitis media) or invasive disease [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/50,58\" class=\"abstract_t\">50,58</a>]. Genomic analysis of nasopharyngeal isolates from children with sickle cell disease who were vaccinated with PCV7 clearly indicated a shift away from vaccine serotypes while maintaining virulence genes [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/59\" class=\"abstract_t\">59</a>]. This suggests that non-vaccine serotypes are circulating in the sickle cell population and they appear to remain virulent [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/59\" class=\"abstract_t\">59</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Staphylococcus aureus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nasal carriage of <em>Staphylococcus aureus</em> in children appears to be inversely related to NP carriage of pneumococcal vaccine serotypes [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/60,61\" class=\"abstract_t\">60,61</a>]. A potential concern with <em>S. aureus</em> carriage is the increasing frequency of community-associated methicillin-resistant <em>S. aureus</em> infections (CA-MRSA). (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-infections-in-children-epidemiology-and-clinical-spectrum#H14\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus infections in children: Epidemiology and clinical spectrum&quot;, section on 'CA-MRSA infection'</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Herd effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunization of children with conjugate vaccines also may reduce NP colonization among their unvaccinated younger siblings, other unvaccinated household contacts, and community members [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/41,47,53,62-64\" class=\"abstract_t\">41,47,53,62-64</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">ANTIBIOTIC RESISTANCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The resistance of pneumococci to a variety of antimicrobial agents has become a worldwide health problem (see <a href=\"topic.htm?path=resistance-of-streptococcus-pneumoniae-to-beta-lactam-antibiotics\" class=\"medical medical_review\">&quot;Resistance of Streptococcus pneumoniae to beta-lactam antibiotics&quot;</a> and <a href=\"topic.htm?path=resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides\" class=\"medical medical_review\">&quot;Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamides, and ketolides&quot;</a>). The effects of routine 7-valent pneumococcal conjugate vaccine (PCV7) immunization in the United States on antibiotic susceptibility patterns of invasive and nasopharyngeal (NP) isolates are discussed in this section.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Invasive isolates</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Data from Active Bacterial Core surveillance areas in the United States indicate declines in antibiotic-nonsusceptible invasive pneumococcal disease (IPD) after the introduction to PCV7 in 2000 (<a href=\"image.htm?imageKey=PEDS%2F54045\" class=\"graphic graphic_figure graphicRef54045 \">figure 3</a>) and after PCV was replaced with PCV13 in 2010 [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/65-67\" class=\"abstract_t\">65-67</a>]. Surveillance from eight children's hospitals in the United States also found a decline in the proportion of isolates nonsusceptible to penicillin and <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">ceftriaxone</a> after the introduction of PCV13 [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/24\" class=\"abstract_t\">24</a>]. Susceptibility results for <a href=\"topic.htm?path=erythromycin-drug-information\" class=\"drug drug_general\">erythromycin</a>, <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a>, and <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> were unchanged.</p><p>Ongoing surveillance is necessary. Although the rate of IPD and antibiotic resistance among IPD isolates continues to decline, increasing proportions of antibiotic nonsusceptible IPD isolates are serotypes that are not included in PCV13 (eg, 35B, 15B, 23A, 23B) have been reported [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/68,69\" class=\"abstract_t\">68,69</a>].</p><p>Two factors are thought to be responsible for the reduction in antibiotic-resistant strains in the pneumococcal conjugate vaccine era [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/47,70\" class=\"abstract_t\">47,70</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immunization with PCV decreases acquisition of vaccine serotypes that are antibiotic-resistant</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recipients of PCV receive less antibiotic therapy than nonvaccinated children, further reducing the selective pressure to acquire resistant strains</p><p/><p>Continued surveillance is necessary. In population-based surveillance during 2007, serotypes 15A, 23A, 35B, and 6C (which are not included in PCV13) accounted for 32 percent of invasive isolates nonsusceptible to penicillin [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/71\" class=\"abstract_t\">71</a>]. More recent surveillance studies continue to note increased proportions of penicillin-nonsusceptible non-PCV13 serotypes (eg, 35B) among invasive isolates [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/68,69\" class=\"abstract_t\">68,69</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">NP isolates</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Universal vaccination of infants appears to have an effect on the antibiotic resistance of strains carried in the nasopharynx as well as on those causing invasive disease. However, the effects are inconsistent, as illustrated by the following observations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a convenience sample of children (&lt;5 years) in Alaska, the proportion of nonsusceptible NP isolates remained unchanged between 2000 and 2010 (range 28 to 37 percent), predominantly because an increase in penicillin-intermediate non-PCV7 NP isolates (13 to 24 percent) was offset by a decrease in penicillin-resistant non-PCV7 NP isolates (23 to 9 percent) [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/72\" class=\"abstract_t\">72</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A report from St. Louis, Missouri, noted a decrease in the prevalence of pneumococcal isolates nonsusceptible to penicillin in the NP cultures of children &lt;7 years with acute respiratory infections (from 25 to 12 percent between 2000 and 2004) [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/73\" class=\"abstract_t\">73</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Surveillance of Massachusetts children &lt;7 years found that overall NP carriage of penicillin-nonsusceptible pneumococci was similar between 2001 and 2009 [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/54\" class=\"abstract_t\">54</a>]. However, penicillin nonsusceptibility increased among serotypes contained in PCV13 (particularly 19A). Multilocus sequence typing of isolates demonstrated expansion of previously recognized clones of nonvaccine serotypes (eg, 19A, 15A, and 35B), emergence of new clones, and serotype switching, but no evidence of de novo acquisition of resistance. (See <a href=\"#H7\" class=\"local\">'Non-PCV serotypes'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>NP swabs obtained from children 6 to 59 months presenting to an emergency department in Atlanta after introduction of PCV13 indicated a decrease in nonsusceptibility to <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">ceftriaxone</a> (22.6 to 3 percent) and penicillin (24 to 3 percent) between 2010 and 2013 [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/44\" class=\"abstract_t\">44</a>].</p><p/><p>The inconsistency of the above observations suggests that factors other than immunization with PCV may play a role in the antibiotic susceptibility patterns of pneumococcal isolates from the nasopharynx. The increased use of <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> may be one such factor [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/74\" class=\"abstract_t\">74</a>].</p><p>These reports highlight the need to continue to monitor the antibiotic resistance patterns of strains of pneumococcus carried in the nasopharynx and the use of antibiotics with potential to promote multidrug resistance.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">VACCINE LIMITATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The use of pneumococcal conjugate vaccines in children has reduced the incidence of invasive pneumococcal disease. However, the issue of eliminating noninvasive disease remains critical. Even if the vaccines as currently formulated substantially decrease the incidence of upper respiratory infection, the effect is not likely to be permanent.</p><p>The hallmark of pneumococci is their ease of natural DNA transformation as evidenced by the diversity and rapidity of spread of antibiotic resistance. As has been demonstrated, a strain can enter a daycare center as one serotype and acquire another serotype capsule within just a few days [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/75\" class=\"abstract_t\">75</a>].</p><p>The molecular flexibility in the capsular locus is based upon its modular gene structure [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/76\" class=\"abstract_t\">76</a>]. There are no known limits to capsular exchangeability. Under antibody selective pressure, pneumococci can be expected to quickly evolve to circumvent vaccines that contain a limited number of serotypes. As described above, there are data to suggest this process may have begun. The only long-term solution to this problem is the development of a vaccine containing one or several protective protein antigens from pneumococcus, rather than serogroup-specific polysaccharide antigens [<a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/77\" class=\"abstract_t\">77</a>].</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=why-does-my-child-need-vaccines-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Why does my child need vaccines? (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=vaccines-for-infants-and-children-age-0-to-6-years-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The incidence of invasive pneumococcal disease (IPD) in the United States has declined dramatically since the pneumococcal conjugate vaccine was added to the routine childhood immunization schedule (<a href=\"image.htm?imageKey=PEDS%2F64834\" class=\"graphic graphic_figure graphicRef64834 \">figure 1</a>). The greatest decline has been noted in pneumococcal bacteremia without a focus. (See <a href=\"#H2\" class=\"local\">'Efficacy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The large decline in cases of IPD caused by PCV7 vaccine serotypes (<a href=\"image.htm?imageKey=PEDS%2F77274\" class=\"graphic graphic_table graphicRef77274 \">table 1</a>) was accompanied by a small increase in the number of cases of IPD caused by nonvaccine serotypes (eg, replacement serotypes) (<a href=\"image.htm?imageKey=PEDS%2F64834\" class=\"graphic graphic_figure graphicRef64834 \">figure 1</a>). Most of the replacement serotypes are included in PCV13, which has replaced PCV7 in the United States. (See <a href=\"#H9889776\" class=\"local\">'Invasive disease caused by nonvaccine serotypes'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Widespread use of PCV7 was associated with an increase in the proportion of cases of IPD associated with pneumonia <span class=\"nowrap\">and/or</span> empyema. (See <a href=\"topic.htm?path=epidemiology-clinical-presentation-and-evaluation-of-parapneumonic-effusion-and-empyema-in-children\" class=\"medical medical_review\">&quot;Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children&quot;</a> and <a href=\"topic.htm?path=pneumococcal-pneumonia-in-children#H8\" class=\"medical medical_review\">&quot;Pneumococcal pneumonia in children&quot;, section on 'Effusion/empyema'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among children receiving the 7-valent vaccine, serotype 19A was an important cause of IPD by replacement serotypes. Serotype 19A is included in the <a href=\"topic.htm?path=pneumococcal-conjugate-vaccine-13-valent-drug-information\" class=\"drug drug_general\">13-valent pneumococcal conjugate vaccine</a> introduced in 2010. However, it remains an important cause of IPD. (See <a href=\"#H4\" class=\"local\">'Serotype 19A'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Universal infant immunization does not appear to have affected the overall rate of carriage of pneumococcus in the nasopharynx. However, universal immunization has reduced carriage of vaccine serotypes and increased carriage of nonvaccine serotypes and <em>Staphylococcus aureus</em>. The clinical implications of these changes in nasopharyngeal colonization remain to be determined. (See <a href=\"#H5\" class=\"local\">'Nasopharyngeal flora'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Universal infant immunization has been associated with a decrease in the rate of penicillin-nonsusceptible and multiple antibiotic-nonsusceptible IPD (<a href=\"image.htm?imageKey=PEDS%2F54045\" class=\"graphic graphic_figure graphicRef54045 \">figure 3</a>). (See <a href=\"#H11\" class=\"local\">'Invasive isolates'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Data regarding the effects of universal infant immunization on the antibiotic resistance patterns of isolates from the nasopharynx are inconsistent. Resistance may be increased through the expansion of clones of antibiotic-resistant nonvaccine serotypes. (See <a href=\"#H12\" class=\"local\">'NP isolates'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/1\" class=\"nounderline abstract_t\">Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/2\" class=\"nounderline abstract_t\">American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000; 106:362.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/3\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59:258.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/4\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005; 54:893.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/5\" class=\"nounderline abstract_t\">Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004; 113:443.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/6\" class=\"nounderline abstract_t\">Byington CL, Samore MH, Stoddard GJ, et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 2005; 41:21.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/7\" class=\"nounderline abstract_t\">Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007; 297:1784.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/8\" class=\"nounderline abstract_t\">Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007; 26:468.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/9\" class=\"nounderline abstract_t\">Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007; 196:1346.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/10\" class=\"nounderline abstract_t\">Schutze GE, Tucker NC, Mason EO Jr. Impact of the conjugate pneumococcal vaccine in arkansas. Pediatr Infect Dis J 2004; 23:1125.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/11\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008; 57:144.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/12\" class=\"nounderline abstract_t\">Jacobs MR, Good CE, Bajaksouzian S, Windau AR. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis 2008; 47:1388.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/13\" class=\"nounderline abstract_t\">Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009; 360:244.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/14\" class=\"nounderline abstract_t\">Park IH, Moore MR, Treanor JJ, et al. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 2008; 198:1818.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/15\" class=\"nounderline abstract_t\">Carvalho Mda G, Pimenta FC, Gertz RE Jr, et al. PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. J Clin Microbiol 2009; 47:554.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/16\" class=\"nounderline abstract_t\">Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/17\" class=\"nounderline abstract_t\">Byington CL, Hulten KG, Ampofo K, et al. Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah. J Clin Microbiol 2010; 48:520.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/18\" class=\"nounderline abstract_t\">Hsu KK, Shea KM, Stevenson AE, et al. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr Infect Dis J 2010; 29:289.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/19\" class=\"nounderline abstract_t\">Techasaensiri C, Messina AF, Katz K, et al. Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas. Pediatr Infect Dis J 2010; 29:294.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/20\" class=\"nounderline abstract_t\">Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378:1962.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/21\" class=\"nounderline abstract_t\">Green MC, Mason EO, Kaplan SL, et al. Increase in prevalence of Streptococcus pneumoniae serotype 6C at Eight Children's Hospitals in the United States from 1993 to 2009. J Clin Microbiol 2011; 49:2097.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/22\" class=\"nounderline abstract_t\">Yildirim I, Stevenson A, Hsu KK, Pelton SI. Evolving picture of invasive pneumococcal disease in massachusetts children: a comparison of disease in 2007-2009 with earlier periods. Pediatr Infect Dis J 2012; 31:1016.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/23\" class=\"nounderline abstract_t\">Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15:301.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/24\" class=\"nounderline abstract_t\">Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32:203.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/25\" class=\"nounderline abstract_t\">Iroh Tam PY, Madoff LC, Coombes B, Pelton SI. Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine. Pediatrics 2014; 134:210.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/26\" class=\"nounderline abstract_t\">Black S. Changing epidemiology of invasive pneumococcal disease: a complicated story. Clin Infect Dis 2008; 47:485.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/27\" class=\"nounderline abstract_t\">Fenoll A, Aguilar L, Granizo JJ, et al. Has the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae? J Antimicrob Chemother 2008; 62:1430.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/28\" class=\"nounderline abstract_t\">Moore MR. Rethinking replacement and resistance. J Infect Dis 2009; 199:771.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/29\" class=\"nounderline abstract_t\">Pai R, Moore MR, Pilishvili T, et al. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 2005; 192:1988.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/30\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae--Massachusetts, 2001-2006. MMWR Morb Mortal Wkly Rep 2007; 56:1077.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/31\" class=\"nounderline abstract_t\">Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 2010; 125:429.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/32\" class=\"nounderline abstract_t\">Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 2007; 298:1772.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/33\" class=\"nounderline abstract_t\">Ongkasuwan J, Valdez TA, Hulten KG, et al. Pneumococcal mastoiditis in children and the emergence of multidrug-resistant serotype 19A isolates. Pediatrics 2008; 122:34.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/34\" class=\"nounderline abstract_t\">Xu Q, Pichichero ME, Casey JR, Zeng M. Novel type of Streptococcus pneumoniae causing multidrug-resistant acute otitis media in children. Emerg Infect Dis 2009; 15:547.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/35\" class=\"nounderline abstract_t\">McNeil JC, Hulten KG, Mason EO Jr, Kaplan SL. Serotype 19A is the most common Streptococcus pneumoniae isolate in children with chronic sinusitis. Pediatr Infect Dis J 2009; 28:766.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/36\" class=\"nounderline abstract_t\">Whitney CG. Impact of conjugate pneumococcal vaccines. Pediatr Infect Dis J 2005; 24:729.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/37\" class=\"nounderline abstract_t\">Huang SS, Platt R, Rifas-Shiman SL, et al. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 2005; 116:e408.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/38\" class=\"nounderline abstract_t\">Millar EV, O'Brien KL, Watt JP, et al. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin Infect Dis 2006; 43:8.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/39\" class=\"nounderline abstract_t\">Park SY, Moore MR, Bruden DL, et al. Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children. Pediatr Infect Dis J 2008; 27:335.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/40\" class=\"nounderline abstract_t\">Huang SS, Hinrichsen VL, Stevenson AE, et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 2009; 124:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/41\" class=\"nounderline abstract_t\">Gounder PP, Bruce MG, Bruden DJ, et al. Effect of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae--Alaska, 2008-2012. J Infect Dis 2014; 209:1251.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/42\" class=\"nounderline abstract_t\">Lee GM, Kleinman K, Pelton SI, et al. Impact of 13-Valent Pneumococcal Conjugate Vaccination on Streptococcus pneumoniae Carriage in Young Children in Massachusetts. J Pediatric Infect Dis Soc 2014; 3:23.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/43\" class=\"nounderline abstract_t\">Dunais B, Bruno P, Touboul P, et al. Impact of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae among children attending group daycare in southeastern France. Pediatr Infect Dis J 2015; 34:286.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/44\" class=\"nounderline abstract_t\">Desai AP, Sharma D, Crispell EK, et al. Decline in Pneumococcal Nasopharyngeal Carriage of Vaccine Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Atlanta, Georgia. Pediatr Infect Dis J 2015; 34:1168.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/45\" class=\"nounderline abstract_t\">Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996; 174:1271.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/46\" class=\"nounderline abstract_t\">Mbelle N, Huebner RE, Wasas AD, et al. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999; 180:1171.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/47\" class=\"nounderline abstract_t\">Dagan R, Givon-Lavi N, Zamir O, Fraser D. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J 2003; 22:532.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/48\" class=\"nounderline abstract_t\">Pelton SI, Loughlin AM, Marchant CD. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J 2004; 23:1015.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/49\" class=\"nounderline abstract_t\">Ghaffar F, Barton T, Lozano J, et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 2004; 39:930.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/50\" class=\"nounderline abstract_t\">Hanage WP, Huang SS, Lipsitch M, et al. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis 2007; 195:347.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/51\" class=\"nounderline abstract_t\">O'Brien KL, Millar EV, Zell ER, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis 2007; 196:1211.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/52\" class=\"nounderline abstract_t\">Nahm MH, Lin J, Finkelstein JA, Pelton SI. Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis 2009; 199:320.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/53\" class=\"nounderline abstract_t\">van Gils EJ, Veenhoven RH, Hak E, et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA 2009; 302:159.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/54\" class=\"nounderline abstract_t\">Wroe PC, Lee GM, Finkelstein JA, et al. Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J 2012; 31:249.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/55\" class=\"nounderline abstract_t\">Grant LR, Hammitt LL, O'Brien SE, et al. Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage Among American Indians. Pediatr Infect Dis J 2016; 35:907.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/56\" class=\"nounderline abstract_t\">Kaur R, Casey JR, Pichichero ME. Emerging Streptococcus pneumoniae Strains Colonizing the Nasopharynx in Children After 13-valent Pneumococcal Conjugate Vaccination in Comparison to the 7-valent Era, 2006-2015. Pediatr Infect Dis J 2016; 35:901.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/57\" class=\"nounderline abstract_t\">van Gils EJ, Veenhoven RH, Hak E, et al. Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA 2010; 304:1099.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/58\" class=\"nounderline abstract_t\">Long SS. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine. Clin Infect Dis 2005; 41:30.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/59\" class=\"nounderline abstract_t\">Carter R, Wolf J, van Opijnen T, et al. Genomic analyses of pneumococci from children with sickle cell disease expose host-specific bacterial adaptations and deficits in current interventions. Cell Host Microbe 2014; 15:587.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/60\" class=\"nounderline abstract_t\">Regev-Yochay G, Dagan R, Raz M, et al. Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in Children. JAMA 2004; 292:716.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/61\" class=\"nounderline abstract_t\">Bogaert D, van Belkum A, Sluijter M, et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet 2004; 363:1871.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/62\" class=\"nounderline abstract_t\">Loughlin AM, Hsu K, Silverio AL, et al. Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts' children. Pediatr Infect Dis J 2014; 33:504.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/63\" class=\"nounderline abstract_t\">Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis 2008; 47:989.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/64\" class=\"nounderline abstract_t\">Hammitt LL, Bruden DL, Butler JC, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 2006; 193:1487.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/65\" class=\"nounderline abstract_t\">Hampton LM, Farley MM, Schaffner W, et al. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis 2012; 205:401.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/66\" class=\"nounderline abstract_t\">Tomczyk S, Lynfield R, Schaffner W, et al. Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine. Clin Infect Dis 2016; 62:1119.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/67\" class=\"nounderline abstract_t\">Moore MR, Link-Gelles R, Schaffner W, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med 2016; 4:399.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/68\" class=\"nounderline abstract_t\">Olarte L, Barson WJ, Barson RM, et al. Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children. Clin Infect Dis 2015; 61:767.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/69\" class=\"nounderline abstract_t\">Richter SS, Diekema DJ, Heilmann KP, et al. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother 2014; 58:6484.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/70\" class=\"nounderline abstract_t\">Klugman KP. Vaccination: a novel approach to reduce antibiotic resistance. Clin Infect Dis 2004; 39:649.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/71\" class=\"nounderline abstract_t\">Gertz RE Jr, Li Z, Pimenta FC, et al. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis 2010; 201:770.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/72\" class=\"nounderline abstract_t\">Gounder PP, Brewster M, Bruce MG, et al. Impact of the Pneumococcal Conjugate Vaccine and Antibiotic Use on Nasopharyngeal Colonization by Antibiotic Nonsusceptible Streptococcus pneumoniae, Alaska, 2000[FIGURE DASH]2010. Pediatr Infect Dis J 2015; 34:1223.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/73\" class=\"nounderline abstract_t\">Garbutt J, Rosenbloom I, Wu J, Storch GA. Empiric first-line antibiotic treatment of acute otitis in the era of the heptavalent pneumococcal conjugate vaccine. Pediatrics 2006; 117:e1087.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/74\" class=\"nounderline abstract_t\">Greenberg D, Givon-Lavi N, Sharf AZ, et al. The association between antibiotic use in the community and nasopharyngeal carriage of antibiotic-resistant Streptococcus pneumoniae in Bedouin children. Pediatr Infect Dis J 2008; 27:776.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/75\" class=\"nounderline abstract_t\">Nesin M, Ramirez M, Tomasz A. Capsular transformation of a multidrug-resistant Streptococcus pneumoniae in vivo. J Infect Dis 1998; 177:707.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/76\" class=\"nounderline abstract_t\">Caimano MJ, Hardy GG, Yother J. Capsule genetics in Streptococcus pneumoniae and a possible role for transposition in the generation of the type 3 locus. Microb Drug Resist 1998; 4:11.</a></li><li><a href=\"https://www.uptodate.com/contents/impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states/abstract/77\" class=\"nounderline abstract_t\">Lee CJ, Banks SD, Li JP. Virulence, immunity, and vaccine related to Streptococcus pneumoniae. Crit Rev Microbiol 1991; 18:89.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 6019 Version 19.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H15\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EFFICACY</a></li><li><a href=\"#H9889776\" id=\"outline-link-H9889776\">INVASIVE DISEASE CAUSED BY NONVACCINE SEROTYPES</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Serotype 19A</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">NASOPHARYNGEAL FLORA</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">PCV serotypes</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Non-PCV serotypes</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Staphylococcus aureus</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Herd effects</a></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">ANTIBIOTIC RESISTANCE</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">Invasive isolates</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">NP isolates</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">VACCINE LIMITATIONS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H14\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/6019|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/64834\" class=\"graphic graphic_figure\">- Rates of IPD after PCV7</a></li><li><a href=\"image.htm?imageKey=PEDS/96718\" class=\"graphic graphic_figure\">- Trends IPD young children 2006-2013</a></li><li><a href=\"image.htm?imageKey=PEDS/54045\" class=\"graphic graphic_figure\">- Nonsusceptibility invasive pneumococcal isolates children</a></li></ul></li><li><div id=\"PEDS/6019|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/77274\" class=\"graphic graphic_table\">- Pneumococcal vaccines</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-otitis-media-in-children-epidemiology-microbiology-clinical-manifestations-and-complications\" class=\"medical medical_review\">Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-presentation-and-evaluation-of-parapneumonic-effusion-and-empyema-in-children\" class=\"medical medical_review\">Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=invasive-pneumococcal-streptococcus-pneumoniae-infections-and-bacteremia\" class=\"medical medical_review\">Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-infections-in-children-epidemiology-and-clinical-spectrum\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus infections in children: Epidemiology and clinical spectrum</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vaccines-for-infants-and-children-age-0-to-6-years-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=why-does-my-child-need-vaccines-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Why does my child need vaccines? (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-children\" class=\"medical medical_review\">Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pneumococcal-streptococcus-pneumoniae-polysaccharide-vaccines-in-children\" class=\"medical medical_review\">Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pneumococcal-pneumonia-in-children\" class=\"medical medical_review\">Pneumococcal pneumonia in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pneumococcal-vaccination-in-adults\" class=\"medical medical_review\">Pneumococcal vaccination in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=resistance-of-streptococcus-pneumoniae-to-beta-lactam-antibiotics\" class=\"medical medical_review\">Resistance of Streptococcus pneumoniae to beta-lactam antibiotics</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides\" class=\"medical medical_review\">Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamides, and ketolides</a></li></ul></div></div>","javascript":null}